1 |
Shah P, Jogani V, Bagchi T and Misra A, Role of Caco-2 cell monolayers in prediction of intestinal drug absorption, Biotechnol. Prog., 22, 186-98 (2006)
DOI
ScienceOn
|
2 |
Tang F, Horie K and Borchardt RT, Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?, Pharm. Res., 19, 765-72 (2002)
DOI
ScienceOn
|
3 |
Takamatsu N, Kim ON, Welage LS, Idkaidek NM, Hayashi Y, Barnett J, Yamamoto R, Lipka E, Lennernäs H, Hussain A, Lesko L and Amidon GL., Human jejunal permeability of two polar drugs: cimetidine and ranitidine, Pharm. Res., 18, 742-4 (2001)
DOI
ScienceOn
|
4 |
C-Y. Wu and L.Z. Benet, Predicting drug disposition via application of BCS Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system, Pharm. Res., 22, 11-23 (2005)
DOI
|
5 |
R. Huang, D.J. Murry, D. Kolwankar, S.D. Hall and D.R. Foster, Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines, Biochem. Pharmacol., 71, 695-1704 (2006)
|
6 |
A. Geick, M. Eichelbaum and O. Burk, Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin, J. Biol. Chem., 276, 14581-7 (2001)
DOI
ScienceOn
|
7 |
Volpe DA., Variability in Caco-2 and MDCK cell-based intestinal permeability assays, J. Pharm. Sci., 97, 712-25, (2008)
DOI
ScienceOn
|
8 |
G.L. Amidon, H. Lennernas, V.P. Shah and J.R. Crison, A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413-420 (1995)
DOI
|
9 |
Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernäs H and Karlen A., Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach, J. Med. Chem., 41, 4939-49 (1998)
DOI
ScienceOn
|
10 |
Lobenberg R and Amidon GL., Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards, Eur. J. Pharm. Biopharm., 50, 3-12 (2000)
DOI
ScienceOn
|
11 |
R. L. Juliano and V. Ling., A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochem. Biophys. Acta., 455, 152-162 (1976)
DOI
ScienceOn
|
12 |
A. H. Schinkel, C. A. Mol, E. Wagenaar, L. van Deemter, J. J. Smit and P. Borst. Multidrug resistance and the role of Pglycoprotein knockout mice, Eur. J. Cancer, 31A, 1295-1298 (1995)
|
13 |
Takamatsu N, Welage LS, Idkaidek NM, Liu DY, Lee PI, Hayashi Y, Rhie JK, Lennernas H, Barnett JL, Shah VP, Lesko L and Amidon GL, Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion, Pharm. Res., 14, 1127-32 (1997)
DOI
ScienceOn
|
14 |
Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H and Tokuda H, Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells, Eur. J. Pharm. Sci., 10, 195-204 (2000)
DOI
ScienceOn
|